Context Therapeutics Q2 2024 Adj EPS $(0.04) Beats $(0.07) Estimate
Portfolio Pulse from Benzinga Newsdesk
Context Therapeutics (NASDAQ:CNTX) reported a Q2 2024 adjusted EPS of $(0.04), beating the analyst consensus estimate of $(0.07) by 42.86%.
August 07, 2024 | 9:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Context Therapeutics reported a Q2 2024 adjusted EPS of $(0.04), beating the analyst consensus estimate of $(0.07) by 42.86%.
The better-than-expected EPS indicates stronger financial performance than anticipated, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100